Sugi Predict

Sugi Predict / Compounds / SCHEMBL4914342

SCHEMBL4914342

SCHEMBL4914342

CCCCCN1CCN(C(C)=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GNAI3 P08754 1/20 0.50
▸ GNAO1 P09471 1/20 0.50
▸ GNAI1 P63096 1/20 0.50
▸ PIK3CD O00329 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ THRB P10828 7/20 0.49
▸ HTR7 P34969 4/20 0.49
▸ PAOX Q6QHF9 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ USP2 O75604 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ KDM1A O60341 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27553097 0.98 GNAI3 (0.53) GNAI3GNAO1GNAI1PIK3CDCYP1A2
SCHEMBL19865695 0.98 GNAI3 (0.53) GNAI3GNAO1GNAI1PIK3CDCYP1A2
SCHEMBL19710765 0.98 GNAI3 (0.53) GNAI3GNAO1GNAI1PIK3CDCYP1A2
SCHEMBL4902299 0.98 GNAI3 (0.53) GNAI3GNAO1GNAI1PIK3CDCYP1A2
SCHEMBL4910227 0.94 CYP1A2 (0.52) PIK3CDCYP1A2TDP1THRBHTR7
SCHEMBL24694352 0.86 CYP1A2 (0.52) PIK3CDCYP1A2TDP1HTR7PAOX
SCHEMBL2619225 0.85 CYP1A2 (0.56) PIK3CDCYP1A2TDP1THRBHTR7
SCHEMBL1098392 0.84 PIK3CD (0.50) PIK3CDCYP1A2TDP1HTR7PAOX
SCHEMBL1098390 0.84 PIK3CD (0.50) PIK3CDCYP1A2TDP1HTR7PAOX
SCHEMBL23518625 0.84 CYP2D6 (0.50) CYP1A2THRBUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4393922-A1 IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-07-03 — — EP disclosed
WO-2024073626-A2 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS NUVATION BIO INC. (US) 2024-04-04 — — WO disclosed
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11718758-B2 Aqueous dispersion of colored particles MITSUBISHI PENCIL COMPANY, LIMITED (JP) 2023-08-08 — — US disclosed
US-11679109-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-06-20 — — US disclosed
US-20230159495-A1 COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) 2023-05-25 — — US disclosed
EP-3307742-B1 METHODS OF TREATING OR PREVENTING A PROTEOPATHY USHER III INITIATIVE INC (US) 2022-05-18 — — EP disclosed
WO-2019214546-A1 FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 (CN) 2019-11-14 — — WO disclosed
EP-2701510-B1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE INC (US) 2017-02-15 — — EP disclosed
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 — — US disclosed
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 — — US disclosed
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION WAKAMOTO PHARMACEUTICAL CO., LTD (JP) 2008-03-27 — — US disclosed
EP-1820799-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION Wakamoto Pharmaceutical Co., Ltd. (JP) 2007-08-22 — — EP disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 — — US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION GABRA5, GABRA1, GABRB1 GNAI3 1131/4885GNAO1 1472/4885GNAI1 988/4885
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 GNAI3 3162/4885GNAO1 3206/4885GNAI1 3170/4885
US-20230159495-A1 COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF FIBP, FGFR2, FGFR1 GNAI3 346/4885GNAO1 1120/4885GNAI1 260/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 GNAI3 1664/4885GNAO1 2977/4885GNAI1 1458/4885
US-11679109-B2 SMARCA degraders and uses thereof SMARCA1, SMARCA2, SMARCC2 GNAI3 3162/4885GNAO1 3206/4885GNAI1 3170/4885
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 GNAI3 294/4885GNAO1 860/4885GNAI1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.